SNPHY (Santen Pharmaceutical Co) Beneish M-Score: -2.57 (As of Jun. 25, 2026)


SNPHY Santen Pharmaceutical Co Ltd SNPHY
87 GF Score
Price $12.36
GF Value $10.15
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Beneish M-Score?

Santen Pharmaceutical Co SNPHY 87 Beneish M-Score is -2.57 as of Jun. 25, 2026. GuruFocus rates SNPHY with a GF Score™ of 87/100 and a GF Value™ of $10.15 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 911 Drug Manufacturers companies, Santen Pharmaceutical Co ranks better than 56.42% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.57 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Santen Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

SNPHY' s Beneish M-Score Range Over the Past 10 Years
Min: -3.13   Med: -2.67   Max: -2.07
Current: -2.57

During the past 13 years, the highest Beneish M-Score of Santen Pharmaceutical Co was -2.07. The lowest was -3.13. And the median was -2.67.


Santen Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Beneish M-Score Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.62 -3.05 -3.13 -2.72 -2.57

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.72 -2.72 -2.47 -2.35 -2.57

SNPHY vs LLY, JNJ, ABBV: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Beneish M-Score falls into.


SNPHY
87GF Score
Santen Pharmaceutical Co Ltd SNPHY
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Santen Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.973+0.528 * 0.9812+0.404 * 1.0032+0.892 * 0.9653+0.115 * 0.8875
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0474+4.679 * -0.014584-0.327 * 0.979
=-2.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $452 Mil.
Revenue was 509.577 + 467.46 + 467.609 + 475.743 = $1,920 Mil.
Gross Profit was 326.4 + 261.354 + 271.075 + 256.901 = $1,116 Mil.
Total Current Assets was $1,442 Mil.
Total Assets was $2,666 Mil.
Property, Plant and Equipment(Net PPE) was $492 Mil.
Depreciation, Depletion and Amortization(DDA) was $121 Mil.
Selling, General, & Admin. Expense(SGA) was $590 Mil.
Total Current Liabilities was $554 Mil.
Long-Term Debt & Capital Lease Obligation was $0 Mil.
Net Income was 98.013 + 50.515 + 54.523 + 40.683 = $244 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0 Mil.
Cash Flow from Operations was 132.207 + 57.39 + 39.584 + 53.432 = $283 Mil.
Total Receivables was $481 Mil.
Revenue was 518.129 + 496.501 + 501.091 + 473.654 = $1,989 Mil.
Gross Profit was 307.915 + 274.571 + 280.727 + 270.911 = $1,134 Mil.
Total Current Assets was $1,505 Mil.
Total Assets was $2,746 Mil.
Property, Plant and Equipment(Net PPE) was $489 Mil.
Depreciation, Depletion and Amortization(DDA) was $104 Mil.
Selling, General, & Admin. Expense(SGA) was $583 Mil.
Total Current Liabilities was $583 Mil.
Long-Term Debt & Capital Lease Obligation was $0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(452.185 / 1920.389) / (481.418 / 1989.375)
=0.235465 / 0.241995
=0.973

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1134.124 / 1989.375) / (1115.73 / 1920.389)
=0.570091 / 0.580992
=0.9812

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1441.606 + 492.272) / 2665.905) / (1 - (1504.787 + 489.435) / 2745.764)
=0.274589 / 0.27371
=1.0032

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1920.389 / 1989.375
=0.9653

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(104.029 / (104.029 + 489.435)) / (121.155 / (121.155 + 492.272))
=0.175291 / 0.197505
=0.8875

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(589.911 / 1920.389) / (583.459 / 1989.375)
=0.307183 / 0.293288
=1.0474

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 553.734) / 2665.905) / ((0 + 582.573) / 2745.764)
=0.20771 / 0.212172
=0.979

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(243.734 - 0 - 282.613) / 2665.905
=-0.014584

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Santen Pharmaceutical Co has a M-score of -2.63 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.57 mean?
Santen Pharmaceutical Co (SNPHY) has a Beneish M-Score of -2.57 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Santen Pharmaceutical Co and its competitors. According to the industry distribution chart, Santen Pharmaceutical Co ranks #397 out of 911 companies in the Drug Manufacturers industry, placing it in the top 43.6%.
Is Santen Pharmaceutical Co's Beneish M-Score too high?
Santen Pharmaceutical Co's current Beneish M-Score is -2.57. Based on the distribution chart, Santen Pharmaceutical Co ranks #397 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Santen Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Beneish M-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #397 out of 911 companies for Beneish M-Score. This puts Santen Pharmaceutical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Beneish M-Score is -2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHY) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.15, compared to a current price of $12.36 — trading 21.8% above its estimated fair value. The current Beneish M-Score is -2.57. Santen Pharmaceutical Co's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHY), the current Beneish M-Score is -2.57 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHY) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $12.36 is trading 21.8% above its estimated GF Value™ of $10.15. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHY:

  • Beneish M-Score: -2.57
  • GF Value™: $10.15 vs. price of $12.36 (21.8% above fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the SNPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santen Pharmaceutical Co Business Description

Other Exchanges 4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
87GF Score

Get the complete analysis for SNPHY

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.36
Price
$10.15
GF Value